SEC Comment Letter 0000000000-23-004531 to Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc.
Date: May 2, 2023 · CIK: 0001788028 · Accession: 0000000000-23-004531
AI Filing Summary & Sentiment
File numbers found in text: 333-271500
Letter
United States securities and exchange commission logo May 2, 2023 Ronald Martell President and Chief Executive Officer Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite #102 Redwood City, CA 94065 Re:Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed April 28, 2023 File No. 333-271500 Dear Ronald Martell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Samantha Eldredge
Show Raw Text
United States securities and exchange commission logo
May 2, 2023
Ronald Martell
President and Chief Executive Officer
Jasper Therapeutics, Inc.
2200 Bridge Pkwy, Suite #102
Redwood City, CA 94065
Re:Jasper Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 28, 2023
File No. 333-271500
Dear Ronald Martell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Samantha Eldredge